Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research

Immune checkpoint inhibitor therapy has revolutionized the field of cancer immunotherapy. Even though it has shown a durable response in some solid tumors, several patients do not respond to these agents, irrespective of predictive biomarker (PD-L1, MSI, TMB) status. Multiple preclinical, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Varayathu, Hrishi, Sarathy, Vinu, Thomas, Beulah Elsa, Mufti, Suhail Sayeed, Naik, Radheshyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193928/
https://www.ncbi.nlm.nih.gov/pubmed/34123767
http://dx.doi.org/10.3389/fonc.2021.559161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193928/
https://www.ncbi.nlm.nih.gov/pubmed/34123767
http://dx.doi.org/10.3389/fonc.2021.559161

Ejemplares similares